London COVID-19 dexamethasone and hyperglycaemia: diabetes de-escalation guidance

Author:

Dr Dipesh Patel, ABCD Chair

Date of the announcement:

Friday, 22 January, 2021

Released on 20th January 2021 by London NHS, London COVID-19 dexamethasone and hyperglycaemia: diabetes de-escalation guidance is now available for download.

Attachments:

COVID-19-Dexamethasone-and-Hyperglycaemia-Guidance-v1.pdf

Address for correspondence: ABCD (Diabetes Care) Ltd, Miria House, 1683b High Street, Knowle, Solihull, West Midlands, B93 0LL

Telephone: 01675 477602 Facsimile: 01361 331 811 Email: info@abcd.care

ABCD (Diabetes Care) is a company limited by shares in England and Wales under company number 7270377, whose registered address is Sterling House, 1 Sheepscar Court, Meanwood Road, Leeds LS7 2BB. Diabetes Care Trust (ABCD) is a registered charity number 1139057, a company limited by guarantee in England and Wales under company number 74248361,whose registered address is Sterling House, 1 Sheepscar Court, Meanwood Road, Leeds LS7 2BB. ABCD (Diabetes Care) Ltd is a wholly owned subsidiary of the Diabetes Care Trust (ABCD) Ltd

ABCD Corporate Pharma Sponsors; Gold: AstraZeneca, Lilly, Novo Nordisk Ltd

ABCD Corporate Pump & Device Supporters, Gold: Abbott Laboratories Ltd, Roche Diabetes Care; Silver: Insulet International Ltd, Medtronic Ltd, Medtrum Ltd, ViCentra; Bronze: Advanced Therapeutics (UK) Ltd, Air Liquide Healthcare Ltd, CamDiab, Dexcom

Read the ABCD statement on pharmaceutical industry funding

London COVID-19 dexamethasone and hyperglycaemia: diabetes de-escalation guidance

Information for HCPs

ABCD Webinar Series

Search form

You are here

London COVID-19 dexamethasone and hyperglycaemia: diabetes de-escalation guidance

Information for HCPs

ABCD Webinar Series